Posted by Michael Wonder on 27 Mar 2026
Eisai and Nuvation Bio announce marketing authorisation application for taletrectinib for the treatment of advanced ROS1 positive non-small cell lung cancer validated by the EMA
26 March 2026 - Additional filings are planned for the UK, Canada and other regions included in Eisai's licensed territories.
Eisai and Nuvation Bio today announced that the EMA has validated the marketing authorisation application for taletrectinib for the treatment of advanced ROS1 positive non-small cell lung cancer.
The filing will follow a standard review timeline.
